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PHARMACODYNAMICS AND 
DRUG ACTION 
Sensitization of human a,- and 
a.,-adrenergic venous responses by 
guanadrel sulfate 
The a,- and af adrenergic venoconstriction in dorsal hand veins of normal subjects was determined by 
infusion of phenylephrine or donidine. Oral administration of prazosin reduced the constriction response 
to phenylephrine but not to clonidine. Subjects were treated for 3 weeks in a randomized crossover design 
with placebo or guanadrel sulfate. Guanadrel reduced sympathetic tone (i.e., plasma norepinephrine and 
norepinephrine release rate), whereas venous responses to phenylephrine and clonidine were both 
augmented during guanadrel treatment. The effect on phenylephrine responses was primarily attributable 
to a decrease in the median effective concentration with a small increase in maximum response. Clonidine 
showed a markedly increased maximum response with a small increase in the median effective 
concentration. Platelet af adrenergic receptors increased slightly but there was no change in the amount 
of platelet pertussis toxin substrate during g-uanadrel treatment. Thus reduction in sympathetic tone in 
normal young men results in increased venous responses to both a,- and aragonists. (CLIN PHARMACOL 
THER 1990;48:537-43.) 
Mohamed A. Sekkarie, MD, Brent M. Egan, MD, Richard R. Neubig, MD, PhD,a 
and Mark A. Supiano, MD' Ann Arbor, Mich. 
The sympathetic nervous system has major patho- 
physiologic roles in disease states, including hyperten- 
sion, and many antihypertensive drugs have their effects 
on the sympathetic nervous system. Vasoconstriction 
by sympathetic stimuli can be mediated by either a,- 
or aradrenergic receptors . rReceptors predominate 
in arterial responses, whereas veins have more prom- 
inent arresponses .3 
Desensitization and supersensitivity of adrenergic re- 
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ceptors can occur in response to pharmacologic inter- 
ventions that alter sympathetic nervous system activity. 
Regulation of P-adrenergic and 0.2-adrenergic4 receptor 
responses has been extensively studied. Less infor- 
mation is available about regulation of a radrenergic 
receptors in humans; however, animal studies have 
shown that a rreceptors in both vascular tissue' and 
salivary glands' are less susceptible to up-regulation 
than a,- or 13-receptors. 
We have previously shown that reduction of 
sympathetic drive by the addition of guanadrel sul- 
fate to the regimen of hypertensive patients treated 
with a diuretic agent caused an increase in the num- 
ber of platelet arreceptors but did not increase 
norepinephrine-mediated vasoconstriction in the fore- 
arm or phenylephrine-induced mydriasis.7 We proposed 
that this discrepancy was attributable to different sub- 
types of the a-adrenergic receptor; the forearm, vaso- 
constrictor and pupillary responses are primarily me- 
diated by an al-receptor, whereas the platelet receptors 
are of the a, type. To directly test this hypothesis and 
to study the regulation of the a,- and aradrenergic 
receptors in a single human tissue, we tested the effect 
of guanadrel sulfate treatment of normal volunteers on 
venoconstrictor responses to the relatively selective a,- 
and aradrenergic agonists phenylephrine and cloni- 
dine, respectively. 
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Table I. Hemodynamic and biochemical data for placebo and guanadrel 
Data are presented as values -± SE. 
NS, p >0.10. 
The mean and SEM of hemodynamic and biochemical variables are shown for the placebo and guanadrel phases of the guanadrel study. Significance was determined 
by paired Student t tests. One-tailed tests were used for all variables except platelet pertussin toxin substrate (G,) because we had previously shown significant decreases 
in all of those values.' 
*A two-tailed test was used for platelet G, because there was no a priori reason or previous data to determine the direction of changes. 
Table II. Effect of guanadrel sulfate on 
rflinorepinephrine kinetics 
Data are from four subjects presented as mean values -± SEM. 
The effect of guanadrel sulfate on ['Hi norepinephrine kinetics was deter- 
mined as previously described IS (see Material and Methods section). The 
kinetic parameters were determined by nonlinear fitting by use of the SAAM29 
program according to a two-compartment model." 
Significance was tested with p values (one-tailed) determined by paired 
Student t test. NS, p > 0.10. 
NE, Rate of norepinephrine release into the extravascular compartment; Q, 
and Q2, masses of norepinephrine in the vascular and extravascular compart- 
ments, respectively; R21, mass flux rate for norepinephrine transfer from com- 
partment 2 to compartment 1; Vc, apparent volume of distribution in the central 
compartment; CNE, concentration of norepinephrine in the plasma compartment. 
METHODS 
Subjects. Normotensive white male volunteers, aged 
18 to 30 years, were recruited through advertisement. 
They were all healthy and stated that they were not 
taking any medications. All subjects signed a written 
informed consent, which was approved by the Medical 
School Committee for Human Research (University of 
Michigan, Ann Arbor, Mich.). 
Prazosin study design. A pilot study was performed 
to determine the effect of an arblocker, prazosin, on 
phenylephrine- and clonidine-induced venoconstric- 
tion. Five normal subjects reported to the laboratory 
after fasting overnight. Catheters and the linear variable 
differential transducer were placed, and venous con- 
striction induced by 640 ng / min phenylephrine and 
1000 ng / min clonidine was measured. Subjects were 
given a single 1 mg oral dose of prazosin, and the study 
was repeated between 60 and 180 minutes after the 
dose. The order of phenylephrine and clonidine was 
randomized for the subjects, with two subjects receiving 
phenylephrine first and three receiving clonidine first. 
Guanadrel study design. The study was a single- 
blind, randomized crossover comparison of 3 weeks of 
guanadrel or placebo. Guanadrel was given at a dose 
of 5 mg b.i.d. for 3 days, 10 mg b.i.d. for another 3 
days, and 15 mg b.i.d. for the remainder of the 3 weeks. 
Home blood pressure measurements were done daily 
by the subjects, and a laboratory blood pressure was 
taken on day 21, when studies were performed. After 
a 2-week washout period in which no medications were 
given, the subject received 3 weeks of treatment with 
the alternate medication and the protocol was repeated. 
Subjects reported to the laboratory at 8 AM of the 
study day after fasting overnight. Vital signs were mea- 
sured, a 16-gauge teflon catheter was inserted into a 
large antecubital vein of each subject and, after 20 
minutes of rest, blood was drawn for measurement of 
catecholamines and platelet arreceptor studies. 
Dorsal hand vein constriction. The change in hand 
vein diameter was measured by use of the linear variable 
differential transducer technique of Aellig.8 The linear 
Placebo Guanadrel p Value 
Systolic blood pressure 
(mm Hg) 
118.3 ± 1.5 115.5 ± 3.4 NS 8 
Diastolic blood pressure 
(mm Hg) 
65.0 ± 4.3 62.8 ± 4.0 NS 8 
Mean blood pressure 
(mm Hg) 
84.6 ± 2.2 80.4 ± 3.4 NS 8 
Heart rate (min-') 66.2 ± 2.0 61.0 ± 3.0 <0.05 8 
Plasma norepinephrine 
(pg/ml) 
185 ± 24 116 ± 18 0.05-0.1 8 
Plasma epinephrine 
(pg/ml) 
71 ± 9 81 ± 15 NS 8 
Platelet a,-receptor 
(fmol/mg) 
97 ± 18 138 ± 30 <0.05 8 
Platelet G, (pmol/mg)* 7.2 ±- 1.4 5.4 ± 0.5 NS 6 
Placebo Guanadrel p Value 
NE, (lig/minim') 1.38 ± 0.33 0.51 ± 0.09 <0.05 (ligim2) 0.52 ± 0.07 0.21 ± 0.05 <0.05 
(11,g/ In2) 29 ± 7 11 ± 2 <0.05 
V, (L) 5.6 ± 0.7 5.0 ± 0.9 NS 
(p,g/min/m2) 0.34 ± 0.06 0.13 ± 0.03 <0.05 
Cr4E (pg/ml) 182 ± 12 83 ± 14 <0.005 
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Table III. Regulation of venous responses to ar and a2-adrenergic agonists 
variable differential transducer is an electromechanical 
device that produces an electrical output proportional 
to the displacement of a movable magnetic core. The 
electrical output is then recorded on a potentiometric 
recorder. In summary, a 25-gauge three-eighths inch 
butterfly needle was placed in a dorsal vein of the hand. 
The line was secured and kept patent by infusing 5% 
dextrose in water at a rate of 0.1 ml/ min by use of an 
infusion pump. The forearm was placed on an arm 
board making a 30° angle from the horizontal, the hand 
was flexed to a horizontal position and gently secured. 
A blood pressure cuff was placed on the upper arm to 
distend the hand vein by inflation of the cuff to 45 mm 
Hg. The linear variable differential transducer was 
placed on the study vein, 1 cm proximal to the needle 
tip. The blood pressure cuff was inflated to 45 mm Hg 
by use of a rapid cuff inflator (Hokanson E-10, D. E. 
Hokanson, Inc., Bellevue, Wash.), and the displace- 
ment of the rod by the congested vein was measured. 
After all the instruments were connected, the baseline 
hand vein diameter was measured twice, then a freshly 
prepared solution of clonidine (aragonist) or phenyl- 
ephrine (a,-antagonist) in 5% dextrose in water was 
infused in stepwise increasing doses 1, 4, 16, 64, and 
128 kg/min for clonidine and 10, 40, 160, 640, and 
1280 kg / min for phenylephrine. Each dose was given 
for 4 minutes while the blood pressure cuff was deflated; 
the cuff was then inflated while the infusion continued 
and the hand vein diameter was measured. All infusions 
were given at a rate of 0.1 ml / min. After the maximal 
dose of one drug, 5% dextrose in water was infused 
and hand vein diameter measurements were repeated 
until they returned to the baseline value; at that time 
the second medication was infused in the same fashion. 
Four patients in each phase received clonidine first and 
the other four received phenylephrine first in both 
phases of the study. The clonidine and phenylephrine 
were given in the same sequence for each patient during 
the guanadrel and placebo period. Four of the eight 
subjects were continued on the placebo or guanadrel 
Response parameters (median effective concentration lEC501 and maximum response) were obtained from nonlinear least-squares analysis of the data in Fig. 3. The 
log of the ECso is shown because that parameter is estimated by the nonlinear least-squares analysis. The calculated EC50 (ng/min) is listed in parentheses. The data 
are shown as fitted parameter ± "estimated SE" provided by the analysis program (InPlot). 
for an additional 2 to 3 days, and norepinephrine kinetic 
studies were performed. 
Plasma catecholamine levels were measured by a ra- 
dioenzymatic method as previously described.' 
Platelet a2-receptor markers. Platelet a2-adrenergic 
receptors were quantitated by measurements of 1 to 10 
nmol / L [31-1]yohimbine binding to platelet membranes 
as described by Supiano et al. 1° Equilibrium dissocia- 
tion constant (Ic) and maximal binding (ILO values 
were determined by nonlinear least-squares fit of spe- 
cific [311]yohimbine binding to a single-site model 
(InPlot, GraphPad Software, San Diego, Calif.). Per- 
tussis toxin substrate in cholate/Lubrol extracts of 
platelet membrane was quantitated by pertussis toxin 
induced [3211ADP ribosylation as described. "'Platelet 
protein was measured by the method of Lowry et al.' 
Norepinephrine kinetics were characterized as 
previously described:5 In brief, tracer doses of 
rflinorepinephrine were infused intravenously for 1 
hour to reach steady-state conditions. Tritium counts 
and plasma norephineprhine concentration were mea- 
sured during the infusion and for 20 minutes after the 
infusion was discontinued. The data were fit to a two- 
compartment model of norepinephrine metabolism in 
humans and extravascular norepinephrine release rate 
(NE2), and the quantity of norepinephrine in the two 
compartments was estimated by nonlinear least-squares 
analysis as described.' 
Statistical analysis. Differences between placebo 
and guanadrel measurements were assessed by paired 
Student t tests. One-tailed tests were done for measure- 
ments for which we hypothesized the direction of 
change on the basis of previous information including 
the following: blood pressure, heart rate, plasma cate- 
cholamine levels, platelet 0.2-receptor number (yohim- 
bine Bmax) and NE2; two-tailed tests were done for plate- 
let pertussis toxin substrate. A p value <0.05 was 
deemed significant. Differences between the placebo 
and guanadrel phases in the clonidine and phenylephrine 
dose response data was analyzed by repeated-measures 
Clonidine 16 ± 1 63 ± 10 0.76 ± 0.11 (6) 1.23 ± 0.32 (17) 
Phenylephrine 64 -± 6 88 ± 4 2.27 ± 0.15 (187) 1.82 -± 0.09 (65) 
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Maximum response 
(% constriction) Log EC, (ng I min) 
Placebo Guanadrel Placebo Guanadrel 
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Fig. 1. Paired plasma norepinephrine level on placebo and 
guanadrel. Symbols show mean and SEM. 
ANOVA. The median effective concentration (EC50) and 
maximum responses for phenylephrine and clonidine 
were determined by nonlinear least-squares fitting of the 
averaged data by use of InPlot (GraphPad Software). 
RESULTS 
In these normotensive subjects the reduction during 
guanadrel treatment of laboratory mean, systolic, and 
diastolic blood pressures was not statistically signifi- 
cant; however, heart rate was significantly reduced 
(Table I). Sympathetic nervous system tone, as assessed 
by both plasma norepinephrine concentration (Fig. 1 
and Table I) and the rate of extravascular norepineph- 
rine release (Table II), was decreased during the guan- 
adrel phase. Plasma epinephrine was not affected. 
As previously reported,' guanadrel treatment was as- 
sociated with a 42% elevation (95% confidence interval 
22% to 106%) in the B,a of platelet [31-I]yohimbine 
binding but this change was of borderline statistical 
significance (p = 0.05 to 0.10). The amount of platelet 
membrane pertussis toxin substrate, as determined by 
pertussis toxin substrate activity, was not altered by 
guanadrel treatment. The smaller number of subjects 
for pertussis toxin substrate measurements was attrib- 
utable to technical difficulties in the preparation of sam- 
ples for this assay. 
0\0 
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Fig. 2. Effect of (xi-blockade by prazosin on the hand vein 
responsiveness to phenylephrine given at 640 Rg/min and 
clonidine at 1000 g/ mm. 
The pharmacologic specificity of effects of the two 
venoconstrictors was tested with the ocrselective an- 
tagonist prazosin. The reduction in hand vein diameter 
caused by phenylephrine and clonidine is shown in Fig. 
2 before and after oral administration of 1 mg prazosin. 
Prazosin reduced the venous responsiveness to phen- 
ylephrine (p = 0.05) but not to clonidine (p > 0.25). 
Dose-response curves for phenylephrine and cloni- 
dine effects on hand vein diameter are shown in Fig. 
3. Because of the variability inherent in these in vivo 
measurements and the small response to clonidine in 
the placebo phase, it was not possible to determine an 
EC50 and maximum response (Rmax) for each individual. 
By averaging the responses we were able to obtain 
reliable estimates of the EC,,, and Rmax under all con- 
ditions. During the placebo phase, phenylephrine pro- 
duced a much greater venoconstrictor response than did 
clonidine (p <0.02, ANOVA) with calculated maxi- 
mum responses of 64% and 16%, respectively (Table 
III). Guanadrel treatment enhanced the responses to 
both agonists but the phenylephrine response remained 
significantly greater than the clonidine response (p < 
0.005, ANOVA). For phenylephrine, there was a sig- 
nificant (p < 0.05, ANOVA) left shift of the curve but 
there was no change in slope (p > 0.1). This was re- 
flected in the nonlinear least-squares fitted parameters 
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Fig. 3. Effect of guanadrel on the contractile effect of phenylephrine (A) and clonidine (B) on 
dorsal hand veins. Dose is given on the abscissa and venoconstriction expressed as a percentage 
of baseline vein diameter is shown on the ordinate. Data are presented as means -± standard 
deviation of eight determinations. Curves are nonlinear least-squares fits of the averaged data to a 
logistic function with a Hill slope of unity. 
by a 2.9-fold lower EC,,, with a minimal increase in 
the maximum response (Table III). In contrast, the max- 
imum response to clonidine was greatly increased 
(Table III), whereas there was no decrease in the EC50 
When tested by ANOVA, clonidine also showed a sig- 
nificant change (p < 0.05) from placebo to guanadrel 
phases, and there was an increased slope of the dose- 
response curve (p < 0.005) that was consistent with 
the increased maximum response (Table III). 
DISCUSSION 
This is the first report of pharmacologic regulation 
of a,- and a,-adrenergic vascular responses in hu- 
mans. Animal studies have shown more prominent up- 
regulation of a,- than aradrenergic receptor numbers 
in salivary glands' and responses in veins.' Our data in 
human dorsal hand veins show that both a,- and ar 
venous responses up-regulate but that the pattern of up- 
regulation is different for the two receptor types. 
0 
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80 
60 
40- 
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p<0.05 ANOVA 
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The maximum response increases for the aragonist, 
whereas the potency increases for the a ragonist. 
The up-regulation of a,- and a2-adrenergic re- 
sponses in human veins after treatment with guanadrel 
sulfate was associated, as expected, with reduced sym- 
pathetic drive. This was indicated by a moderate re- 
duction in circulating norepinephrine and a greater re- 
duction in norepinephrine release, as measured by 
[21-I]norepinephrine tracer kinetics. The prominent ef- 
fect on a-adrenergic vascular responses may be attrib- 
uted to the significant reduction in norepinephrine re- 
lease at the neurovascular junction, as estimated by the 
extravascular norepinephrine release rate, NE2. 
Identification of the a-receptor subtypes involved in 
the venous responses depends in part on the specificity 
of clonidine and phenylephrine as selective agonists. 
In studies on arterial vasoconstriction, the effects of 
clonidine were partially blocked by both yohimbine and 
prazosin, whereas those of methoxamine were blocked 
by prazosin alone.' In our study of clonidine responses, 
there was no significant blockade by prazosin, whereas 
the effects of phenylephrine were substantially reduced 
by prazosin (Fig. 1). The latter observation confirms 
that of Eichler et al. ,16 who showed that oral prazosin 
nearly completely eliminated the venous constriction 
response to phenylephrine. The increased importance 
of a2-receptors in the venous responses to clonidine 
correlates with the observation that a2-receptors play a 
more important functional role in veins than in arteries 
of humans and other species.3'1718 
The pattern of responses to phenylephrine and clo- 
nidine observed here is also consistent with those seen 
for a,- and arresponses in in vitro systems. Generally, 
a,-responses are characterized by substantial receptor 
reserve, whereas a2-responses have less receptor re- 
serve.1920 In a system with receptor reserve, an en- 
hancement in responsiveness can only be expressed in 
an increased potency (decreased EC,o) with no increase 
in the maximal response. This was observed for the a r 
agonist phenylephrine, whereas a substantial increase 
in maximum response was seen for the ar selective 
agonist clonidine. 
In this study, the increase in platelet a,- adrenergic 
receptor numbers after guanadrel treatment (42%) did 
not reach the conventional criterion for statistical sig- 
nificance, whereas our previous study showed a definite 
increase (48% increase): Three differences between the 
studies may explain this discrepancy. First, this study 
had fewer subjects (8 versus 11 subjects). Second, di- 
uretic treatment or the fact that the subjects were hy- 
pertensive in the previous study may have resulted in 
higher basal catecholamine values (303 versus 185 
pg / ml norepinephrine). The higher basal catechol- 
amine levels could have partially down-regulated the 
a2-receptors so that the up-regulation by guanadrel was 
more apparent in the hypertensive subjects. Finally, the 
mechanisms for up-regulation of arreceptors in hy- 
pertensive subjects may be enhanced. 
To assess the role of effector system changes in the 
up-regulation of a2-responses, we studied the effect of 
guanadrel on the inhibitory guanine nucleotide binding 
protein, pertussis toxin substrate in the platelet. No 
effect of guanadrel was seen on the content of pertussis 
toxin substrate as measured by the pertussis toxin sub- 
strate method. As we have reported previously, there 
is a substantial excess of pertussis toxin substrate over 
aradrenergic receptors (50- 100-fold molar excess).12 
Thus, changes in the number of a2-receptors of the 
magnitude observed here might not be expected to re- 
sult in large fractional changes in the amount of per- 
tussis toxin substrate present. Because the venous ar 
response increased threefold, whereas the platelet re- 
ceptor number increased only 40% to 50%, there may 
still be changes in the distal effector coupling mecha- 
nisms. This could be occurring at a locus other than 
pertussis toxin substrate or could be attributable to en- 
hanced efficiency of a2-receptorpertussis toxin sub- 
strate coupling without significant changes in cell con- 
tent of the proteins. Finally, the greater increase in 
response than in receptor number could be attributable 
to the different tissues used for the two measurements. 
In summary, reduction in sympathetic tone by guan- 
adrel is accompanied by enhanced venous responsive- 
ness to both a,- and a2-adrenergic stimuli. This up- 
regulation would be expected to maintain venous tone 
and reduce orthostatic hypotension in this setting of 
decreased sympathetic drive. 
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